Cost/efficacy analysis of preferred Spanish AIDS study group regimens and the dual therapy with lopinavir/ritonavir plus lamivudine for initial ART in HIV infected adults
Copyright © 2015 Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. All rights reserved..
INTRODUCTION: The National AIDS Plan and the Spanish AIDS study group (GESIDA) proposes "preferred regimens" (PR) of antiretroviral treatment (ART) as initial therapy in HIV-infected patients. In 2013, the recommended regimens were all triple therapy regimens. The Gardel Study assessed the efficacy of a dual therapy (DT) combination of lopinavir/ritonavir (LPV/r) plus lamivudine (3TC). Our objective is to evaluate the GESIDA PR and the DT regimen LPV/r+3TC cost/efficacy ratios.
METHODS: Decision tree models were built.
EFFICACY: probability of having viral load <50 copies/mL at week 48. ART regime cost: costs of ART, adverse effects, and drug resistance tests during the first 48 weeks.
RESULTS: Cost/efficacy ratios varied between 5,817 and 13,930 euros per responder at 48 weeks, for the DT of LPV/r+3TC and tenofovir DF/emtricitabine+raltegravir, respectively.
CONCLUSIONS: Taking into account the official Spanish prices of ART, the most efficient regimen was DT of LPV/r+3TC, followed by the triple therapy with non-nucleoside containing regimens.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:34 |
|---|---|
| Enthalten in: |
Enfermedades infecciosas y microbiologia clinica - 34(2016), 7 vom: 01. Aug., Seite 427-30 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gatell Artigas, Josep María [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 09.03.2018 Date Revised 02.12.2018 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.eimc.2015.01.018 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM246874783 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM246874783 | ||
| 003 | DE-627 | ||
| 005 | 20231224144014.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.eimc.2015.01.018 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0822.xml |
| 035 | |a (DE-627)NLM246874783 | ||
| 035 | |a (NLM)25749416 | ||
| 035 | |a (PII)S0213-005X(15)00067-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gatell Artigas, Josep María |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cost/efficacy analysis of preferred Spanish AIDS study group regimens and the dual therapy with lopinavir/ritonavir plus lamivudine for initial ART in HIV infected adults |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.03.2018 | ||
| 500 | |a Date Revised 02.12.2018 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2015 Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. All rights reserved. | ||
| 520 | |a INTRODUCTION: The National AIDS Plan and the Spanish AIDS study group (GESIDA) proposes "preferred regimens" (PR) of antiretroviral treatment (ART) as initial therapy in HIV-infected patients. In 2013, the recommended regimens were all triple therapy regimens. The Gardel Study assessed the efficacy of a dual therapy (DT) combination of lopinavir/ritonavir (LPV/r) plus lamivudine (3TC). Our objective is to evaluate the GESIDA PR and the DT regimen LPV/r+3TC cost/efficacy ratios | ||
| 520 | |a METHODS: Decision tree models were built | ||
| 520 | |a EFFICACY: probability of having viral load <50 copies/mL at week 48. ART regime cost: costs of ART, adverse effects, and drug resistance tests during the first 48 weeks | ||
| 520 | |a RESULTS: Cost/efficacy ratios varied between 5,817 and 13,930 euros per responder at 48 weeks, for the DT of LPV/r+3TC and tenofovir DF/emtricitabine+raltegravir, respectively | ||
| 520 | |a CONCLUSIONS: Taking into account the official Spanish prices of ART, the most efficient regimen was DT of LPV/r+3TC, followed by the triple therapy with non-nucleoside containing regimens | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a AIDS | |
| 650 | 4 | |a Antiretroviral therapy | |
| 650 | 4 | |a Cost | |
| 650 | 4 | |a Coste | |
| 650 | 4 | |a Efficacy | |
| 650 | 4 | |a Efficiency | |
| 650 | 4 | |a Eficacia | |
| 650 | 4 | |a Eficiencia | |
| 650 | 4 | |a HIV | |
| 650 | 4 | |a SIDA | |
| 650 | 4 | |a Terapia antirretroviral | |
| 650 | 4 | |a VIH | |
| 650 | 7 | |a Anti-HIV Agents |2 NLM | |
| 650 | 7 | |a Lopinavir |2 NLM | |
| 650 | 7 | |a 2494G1JF75 |2 NLM | |
| 650 | 7 | |a Lamivudine |2 NLM | |
| 650 | 7 | |a 2T8Q726O95 |2 NLM | |
| 650 | 7 | |a Ritonavir |2 NLM | |
| 650 | 7 | |a O3J8G9O825 |2 NLM | |
| 700 | 1 | |a Arribas López, José Ramón |e verfasserin |4 aut | |
| 700 | 1 | |a Lázaro Y de Mercado, Pablo |e verfasserin |4 aut | |
| 700 | 1 | |a Blasco Bravo, Antonio Javier |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Enfermedades infecciosas y microbiologia clinica |d 1993 |g 34(2016), 7 vom: 01. Aug., Seite 427-30 |w (DE-627)NLM01273425X |x 1578-1852 |7 nnns |
| 773 | 1 | 8 | |g volume:34 |g year:2016 |g number:7 |g day:01 |g month:08 |g pages:427-30 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.eimc.2015.01.018 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 34 |j 2016 |e 7 |b 01 |c 08 |h 427-30 | ||